The race is on for new drugs that suppress appetite, improve glucose regulation and can replace injections. But do they ...
The round is one of Europe’s largest-ever biotech VC deals, signalling investor appetite for the booming weight loss market.
Eli Lilly expects its experimental weight loss pill, orforglipron, to receive approval as early as next year, CEO David Ricks told Bloomberg Jan. 13, according to a Wall Street Journal report.
Ozempic has been approved for diabetes, though it's sometimes still used for weight loss. Rybelsus is a similar drug that's the same price and uses the same ingredient as Ozempic. But Rybelsus is ...
Eli Lilly and Novo Nordisk, which dominate the market with their obesity injections Zepbound and Wegovy, respectively, are both looking to develop next-generation versions. A weight loss pill ...
Eli Lilly (LLY) revised its revenue outlook on Tuesday for the fourth quarter of 2024 on weaker-than-expected demand for its ...
Some people may turn to private healthcare providers in order to get their hands on the weight loss jabs. However, Britons ...
Novo Nordisk A/S’s blockbuster drug Wegovy was targeted for price cuts by the US government and suffered a setback in a new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback